INTRODUCTION {#sec1-1}
============

Low molecular weight heparin (LMWH) is a glycosaminoglycan widely used for its anti-coagulant activity. Venous thromboembolism and unstable angina can be prevented or treated with LMWH.\[[@ref1][@ref2]\] Venous thromboembolism is the third most common cause of death among hospitalized patients. It is also used in the prevention of clots after implantation of a medical device.\[[@ref1]\] Apart from anti-coagulant activity, it is also reported for its use in the therapy of rheumatoid arthritis, asthma, and cancer.\[[@ref3][@ref4][@ref5]\] LMWH shows excellent anti-coagulant activity with less severe toxicities like thrombocytopenia and bleeding.\[[@ref1]\] LMWH is water-soluble macromolecular drug, with a short physiological half-life. On oral administration, it shows very low bioavailability because of its size and negative charge and the poor permeation through the intestinal wall. To overcome this problem, it is administered via the parenteral route.\[[@ref1]\] Formulations approved by Food and Drug Administration are lyophilized powders to be reconstituted into solutions. Repeated parenteral administration that is, intravenous (I.V.)/subcutaneous (s.c.) solutions and therapeutically monitored I.V. infusions are invasive and further, repeated administrations add insult to the existing invasiveness. This is a major problem with currently used therapy with LMWH. To improve the therapy with LMWH, several routes, and several delivery systems were previously investigated.\[[@ref6]\] For instance, Lanke *et al*., investigated oral microspheres along with penetration enhancers to enhance oral bioavailability of LMWH.\[[@ref7]\] In this study, the oral bioavailability of LMWH was enhanced by 21%. Bai *et al*., investigated dendrimers as carriers for pulmonary delivery of LMWH.\[[@ref8]\] This formulation enhanced the bioavailability of LMWH by 40% and was more effective in preventing venous thromboembolism in a rodent model compared with its solution form administered subcutaneously. Similarly, several studies to improve the therapy with LMWH have been investigated. However, these formulations are in the investigational stages only. Parenteral sustained release dosage forms for LMWH was recently addressed in one study by Choubey *et al*.\[[@ref9]\] This study demonstrated better benefits for parenteral sustained release dosage forms for LMWH. However, this is the only study, which addressed this issue so far. More investigations are necessary for clinical realization of such a strategy.

Development of parenteral sustained release dosage forms finds a solution to the problem with current LMWH therapy and this solution is clinically viable. The most convenient and the clinically viable route for sustained release LMWH is parenteral route. Intramuscular (i.m.), s.c., intraperitoneal (i.p.) and I.V. formulations belong to various parenteral formulations. Sustained release parenteral formulations can be administered via any of these aforementioned routes. Significant improvement in the therapy in the form of prolonged release via the parenteral route was achieved with heparin. Heparin implantable dosage forms such as stents, nanoparticles, liposomes are safe for administration in the body and resulted in sustained systemic release of heparin.\[[@ref10][@ref11][@ref12]\] Similar observations can be extrapolated to LMWH, which is a similar molecular as that of heparin. Parenteral sustained release I.V. dosage forms such as microspheres, nanoparticles, liposomes upon administration are immediately engulfed by reticuloendothelial system (RES) in the liver and then slowly releases the drug within RES.\[[@ref13][@ref14]\] To overcome this problem, development of sustained release i.m., s.c., and i.p. nanoparticles are needed. However, precedence has been established with s.c route for LMWH. Presently marketed preparations of LMWH are administered via s.c. route and the dosage forms require frequent administration.\[[@ref1]\] Thus, development of s.c. sustained release dosage forms offer a promising option for LMWH. Thus, the most convenient and the clinically viable route for LMWH nanoparticles is s.c. As per our knowledge, for LMWH, subcutaneously administered sustained release nanoparticles were not reported previously. Thus, the objective of this study was to develop s.c. sustained release nanoparticles of LWMH and further evaluate the formulation for various *in vitro* and *in vivo* properties.

MATERIALS AND METHODS {#sec1-2}
=====================

Materials {#sec2-1}
---------

Low molecular weight heparin (Enoxaparin) was a gift sample from Gland Pharma Pvt. Ltd., (Hyderabad, India). Polylactide co-glycolide (PLGA) (50:50, 85:15) was purchased from PolySciTech, USA. Dichloromethane and polyvinyl alcohol (PVA) were purchased from SD Fine Chemicals Ltd. An ultraviolet (UV) - visible spectrophotometer from Thermo scientific was used. Qsonica probe sonicator, Cooling centrifuge Hittech MIKRO 220 R, Freeze dryer (Mini Lyodel) Chennai, India were used for formulation of Nanoparticles. A JSM-5200 scanning electron microscope (SEM), Japan, was used to study the surface morphology of nanoparticles. Zetasizer Nano ZS (Malvern Instruments, Malvern, United Kingdom) was used to measure the particle size and zeta potential of prepared nanoparticles. Differential scanning calorimeter from Shimadzu, Fourier transform infrared spectrophotometer (FTIR) from Perkin-Elmer and X-ray diffractometer, X-ray powder diffraction (XRPD) from PAN analytical were used. All other ingredients used in this study were of analytical grade.

Methods {#sec2-2}
-------

### Preparation of nanoparticles {#sec3-1}

The LMWH nanoparticles were prepared by the water--in-oil in-water (w/o/w) emulsion and evaporation method. Required quantity of drug was taken in 2 ml of distilled water. To this 10 ml of methylene chloride containing the polymer (PLGA 50:50/PLGA 85:15) was added and emulsified with a probe sonicator (Qsonica) for 30 s at 60 W. The resulting w/o emulsion was then poured in 40 ml of PVA (0.1%) solution and sonicated for 60 s at 60 W using probe sonicator resulting in the formation of w/o/w emulsion. This emulsion was kept on the magnetic stirrer (15 rpm) for 10 min to evaporate methylene chloride.\[[@ref14]\] Nanoparticles were then isolated by centrifugation (Hittich, MIKRO 220R), at 18,000 rpm for 15 min. The supernatant was removed and assayed to find out entrapment efficiency. The nanoparticles were washed three times with deionized water and subjected to freeze drying (Lyophilizer, Mini--Lyodel, Delvac, Chennai, India).

Characterization of the nanoparticles {#sec2-3}
-------------------------------------

### Size and surface analysis {#sec3-2}

The mean diameter of nanoparticles and their surface potential were evaluated with zeta sizer, which was regularly calibrated and validated. Surface morphology was evaluated using SEM. A concentrated aqueous suspension was spread over a slab and dried under vacuum. The sample was shadowed in a cathodic evaporator with gold layer 20 nm thick. Photographs were taken using a JSM-5200 Scanning Electron Microscope (Tokyo, Japan) operated at 20 kV.

### Zeta potential {#sec3-3}

The zeta potential is used to measure the electric charge at the surface of the particles, indicating the physical stability of colloidal systems. The zeta potential was measured using a Zetasizer Nano ZS (Malvern Instruments, Malvern, United Kingdom). The equipment is maintenance-free system, which is regularly calibrated and validated. Samples were diluted with the respective original dispersion medium, which provides information regarding the thickness of the diffuse layer. Diluted nanosuspension was added to the sample cell (quartz cuvette) and was put into the sample holder unit, and zeta potential was measured.

### Encapsulation efficiency {#sec3-4}

The amount of drug entrapped in nanoparticles was determined by turbidimetric assay by measuring the amount of nonentrapped drug in the supernatant recovered after centrifugation. Briefly, 1 ml of supernatant was taken. To this 1 ml of acetate buffer (1M, pH 5) followed by 4 ml of cetylpyridinium solution (0.1%) in NaCl 0.94% was added and assayed for drug release at 500 nm by UV spectrophotometer.\[[@ref15]\]

### In vitro drug release {#sec3-5}

An aliquot of 10 mg of nanoparticles was suspended in flask containing 3 ml of phosphate buffer saline (phosphate-buffered saline 0.011 M, NaCl 0.15 M, pH 7.4), and kept it for stirring (150 rpm) on magnetic stirrer. Entire sample was taken every 24 h up to 10 days and centrifuged for 15 min at 18,000 rpm, using cooling centrifuge (Hittich, MIKRO 220 R). To the pellet obtained after centrifugation, again 3 ml of phosphate buffer saline was added and kept for stirring for further readings. A volume of 1 ml of supernatant was taken, and LMWH was assayed.

### In vivo drug release from low molecular weight heparin nanoparticles {#sec3-6}

The *in vivo* biological activity of LMWH was evaluated by measuring the anti-factor Xa activity with a chromogenic substrate using the standard kit (KRIBIOLISA™ Xa) from Krishgen Bio Systems, Mumbai, India. according to the method described by the supplier.

*In vivo* biological activity of LMWH was investigated in male Wistar rats. All the experiments were conducted according to the guidelines of CPCSEA. The study was approved by Animal Ethical Committee of Synapse Life Sciences, Warangal registered under CPCSEA, India (IAEC No. vcop/VI/2014/10/2). The animals were divided into 5 groups (*n* = 6) as given below. Based on the results of size and surface analysis, encapsulation efficiency, *in vitro* drug release four formulations (F5, F6, F11, F12) were selected for *in vivo* biological activity. LMWH was administered to the control group subcutaneously.

Group 1: S.c. administration of F5Group 2: S.c. administration of F6Group 3: S.c. administration of F11Group 4: S.c. administration of F12Group 5: Control group administered s.c drug solution.

Group 1 received 0.3 ml of F5 nanoparticular formulation. Group 2 received 0.3 ml F6 nanoparticular formulation. Group 3 received the 0.3 ml suspension of formulation F11, Group 4 received the 0.3 ml suspension of F12 formulation. All the rats were administered 4.5 mg/kg equivalent of the drug. After administration of formulations blood samples were collected at 6, 12, 18, 24 h and 2, 3, 4, 5, 6, 7, 8, 9, and 10 days, then plasma was collected and the concentration of drug of drug in plasma was quantified by anti-Xa assay method using standard kit (KRIBIOLISA™ Xa) according to the method described by the supplier. The peak plasma concentration (C~max~) and time to reach the maximum peak concentration (T~max~) and area under the curve (AUC) were obtained as described earlier.\[[@ref16][@ref17]\]

Selection and characterization of optimized formulation {#sec2-4}
-------------------------------------------------------

Using size, zeta potential, encapsulation, *in vitro* and *in vivo* drug release, an optimum formulation that releases the drug for 10 days *in vivo* was selected. The optimized formulation was characterized for various properties as chemical integrity, thermal state and crystalline state using FTIR, differential scanning calorimetry (DSC) and PXRD, respectively, as described earlier.\[[@ref18]\]

Statistics {#sec2-5}
----------

All experiments were done six times and the data were expressed as mean ± standard deviation and Tukey\'s post-hoc test was done to analyze significance of difference between different groups using the statistical analysis software package SPSS (version 16.0, IBM, USA).

RESULTS AND DISCUSSION {#sec1-3}
======================

Studies that addressed parenteral sustained release of LMWH are scanty. A recent study developed a pegylated enoxaparin for sustained s.c. delivery of LMWH. Choubey *et al*. developed polyethylene glycol-LMWH (P-ENX) conjugates for s.c. administration. P-ENX conjugate exhibited enhancement in anti Xa activity by three-fold as compared to free ENX, and it exhibited an increase in AUC by four-fold.\[[@ref9]\] Thus, s.c. administration of this drug a novel approach for extended and enhanced activity of LMWH. Development of subcutaneously administered nanoparticular formulation is another similar attempt that can be investigated for LMWH. In recent years, nanoparticles have become very attractive for their applications in biology and medicine.\[[@ref19]\] In this study, nanoparticles incorporating LMWH were prepared to develop a parenteral sustained release dosage form. The particular focus of the route of administration of these nanoparticles is subcutaneous. Studies on s.c. nanoparticles for sustained systemic release of the active appeared in the scientific literature. They have tremendous potential. S.c. nanoparticles for systemic delivery of antitubercular drugs, tetracycline have been previously reported.\[[@ref20][@ref21]\] One recent study reported s.c. etoposide-loaded solid lipid nanoparticles (ETPL) for local delivery in tumors.\[[@ref22]\] A comparison of s.c., I.V., and i.p. routes has been mentioned to treat Daltons lymphoma in this mice model. The results indicated that s.c. route for nanoparticles was better compared with other two routes. S.c. administration also showed a significant reduction in drug uptake by organs of the reticuloendothelial system (i.e., lung, liver, and spleen), which resulted in longer circulation of ETPL nanoparticles. This route also had a relatively low tissue distribution, which can reduce the systemic side-effects of etoposide. Similar results we envision with s.c. administration of LMWH nanoparticles.

In this study, for the first time, we report s.c. nanoparticles for sustained systemic delivery of the LMWH. The main goals in the design of nanoparticles are to control the particle size, surface properties and release of the active drug.\[[@ref19]\] In this study, we used PLGAs to prepare s.c. LMWH nanoparticles. PLGA is a biocompatible and biodegradable polymer approved by USFDA. Several commercial products utilize this polymer. We successfully fabricated LMWH nanoparticles using PLGA (50:50, 85:15) and different concentration PVA (0.1%, 0.5%, 1%) aqueous solution by employing water-in-oil in-water (w/o/w) emulsion and evaporation method. The compositions are shown in [Table 1](#T1){ref-type="table"}. The particle size of the all the nanoparticle formulations was found between 195 nm and 251 nm. The study of SEM was conducted to confirm the formation and surface morphology of nanoparticles. All the nanoparticles were spherical in shape. These are shown in [Figure 1](#F1){ref-type="fig"}. Particle size of the particles decreased as the concentration of surfactant increased. This may due to low concentration of surfactant, which would fail to stabilizing the nanoparticles and thereby promoting aggregation and then enhancement in particle size. As the concentration of PLGA increased, particle size also increased. The zeta potential of all the particles was between − 22.1 mV and − 35.2 mV. Nanoparticles prepared using PLGA have invariably negative charge, and sometimes depends on the characteristics of the drug encapsulated. Particle size and zeta potential of all the nanoparticle formulations depicted in [Table 2](#T2){ref-type="table"}. The encapsulation efficiency of all the fabricated nanoparticles was found between 46% and 70%. As the concentration of polymer increases, there was an increase in encapsulation efficiency. The lowest encapsulation efficiencies were 46 ± 2 and 48 ± 1.56 found in F1, F6 formulations, which consist of lower amount of polymer concentration (150 mg) and lower surfactant concentration (0.1%). The *in vitro* drug release studies were performed for all the formulations. The results of drug release demonstrated sustained release of drug from all the formulations for 10 days \[[Figure 2](#F2){ref-type="fig"}\]. Among the nanoparticles fabricated with PLGA 50:50 (F1--F6), F5 formulation demonstrated maximum drug release, which was about 38.02% in 10 days and the reason could be attributed to the surfactant concentration. As the concentration of surfactant increased, there was a decrease in particle size of an increase in surface area of the particles, which tends to increase the drug release from the nanoparticles. The same results were demonstrated with nanoparticles fabricated by using PLGA 85:15. F11 and F12 formulations show maximum drug release for 10 days about 37.56% and 36.01%, respectively. The release represented in [Figure 3](#F3){ref-type="fig"}. From the various formulations we prepared, we selected four formulations (F5, F6, F11, F12) for *in vivo* biological activity based on the results of size and surface analysis, encapsulation efficiency, *in vitro* drug release. The selected four formulations were used for measurement of anti-factor Xa activity in rats. Software was used to calculate the pharmacokinetic parameters, and the results are summarized in [Table 3](#T3){ref-type="table"}. Plasma concentration versus time profile of selected formulations and pure drug solution is presented in [Figure 4](#F4){ref-type="fig"}. For pure drug peak plasma concentration, C~max~ was 12.5 μg/ml and T~ma~ × 3 h, and AUC~0-∞~ was 37.84 μg/ml/h. Pharmacokinetic parameters of selected formulations and pure drug solutions are represented in [Table 3](#T3){ref-type="table"}. S.c. nanoparticles exhibited increased C~max~, AUC~0-∞~, and T~max~ values when compared to pure drug solutions for 10 days. Among the four formulations (F5, F6, F11, F12) F6 formulation exhibited peak plasma concentration 9.5 μg/ml at 7^th^ day (T~max~). F6 formulation exhibited a four-fold enhancement (37.485 vs. 158.484 μg/ml/h) in the area under the curve (AUC~0-∞~) From the *in vitro* and *in vivo* drug release data, as well as zeta potential and surface size, an optimum formulation (F6) was selected, and this was further characterized.

###### 

Composition of various nanoparticle formulations

![](JAPTR-6-58-g001)

![*In vitro* drug release profiles of nanoparticle formulations containing low molecular weight heparin prepared using different concentrations of polylactide co-glycolide 50:50 and different concentrations of surfactant (0.1%, 0.5%, 1%)](JAPTR-6-58-g002){#F1}

###### 

Particle size, zeta potential and encapsulation efficiency of all the formulations
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![*In vitro* drug release profiles of nanoparticle formulations containing low molecular weight heparin prepared using different concentrations of polylactide co-glycolide 85:15 (150, 200 mg) and different concentrations of surfactant (0.1%, 0.5%, 1%)](JAPTR-6-58-g004){#F2}

![Plasma concentration-time profiles of selected formulations and low molecular weight heparin solution](JAPTR-6-58-g005){#F3}

###### 

Pharmacokinetic parameters of LMWH and selected formulations
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![Scanning electron microscope picture of low molecular weight heparin nanoparticles](JAPTR-6-58-g007){#F4}

Fourier transforms infrared spectroscopy spectra of drug, polymers, and optimized formulation was recorded. The presence of peaks at the expected range confirmed that the materials taken for the study are genuine, and there were no possible chemical interactions between drug and the excipients. XRPD results yielded interesting results. The drug was crystalline due to the sharp peaks demonstrated in XRPD. With the optimized nanoparticles, there was a small bump in the peak suggesting partial conversion of LMWH to less crystalline form and that may be due to the formation of amorphous form upon formulation. XRPD spectra are shown in [Figure 5](#F5){ref-type="fig"}. The DSC of the pure drug and the optimized formulations is shown in [Figure 6](#F6){ref-type="fig"}. There was a change in the thermograms of pure drug and the optimized formulation, suggesting a change in the physical state of the drug upon formulation. DSC of physical mixture was used as a control. As DSC of the physical mixture was very much similar to that of the optimized formulation, it can be inferred that there was a change in the solid state of the drug upon formulating into the nanoformulation.

![XRPD pattern of LMWH in the optimized formulation ((a) pure drug; (b) optimized formulation](JAPTR-6-58-g008){#F5}

![Differential scanning calorimetry thermograms of low molecular weight heparin in the optimized formulation ((a) pure drug; (b) optimized formulation; (c) physical mixture)](JAPTR-6-58-g009){#F6}

CONCLUSIONS {#sec1-4}
===========

The results of this study revealed that s.c. nanoparticular formulation developed here will be a suitable form for sustained delivery of LMWH. Currently, LMWH is administered subcutaneously or intravenously twice or thrice a day in the form of solution. This could be conveniently avoided with the formulations we developed in our study. This is definitely a new observation and will have a tremendous impact for the therapy in all the diseases where LMWH is useful.
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